Doxorubicin (generic), Adriamycin, Doxil News

Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection Abstract New strategies to self-assemble biocompatible materials into nanoscale, drug-loaded packages with improved therapeutic efficacy are needed for nanomedicine.

Ziopharm Oncology, Inc. achieved positive data from the multicenter randomized Phase II trial of palifosfamide in patients with unresectable or metastatic soft tissue sarcoma.

Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 15th Annual Connective Tissue Oncology Society Meeting taking place in Miami Beach, Florida from November 5 to 7, 2009.

Cancer cells, like bacteria, can develop resistance to drug therapy, leading to relapse of disease.

More than 60% of patients with diffuse large B-cell lymphoma will be cured with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone .

Going smaller could bring better results, especially when it comes to cancer-fighting drugs.

BACKGROUND: The addition of rituximab to CHOP chemotherapy improves outcome in patients with diffuse large B-cell lymphoma .

Tel: +61-03-9479-1517; Fax: +61-03-9479-2467; Email: s.cutts{at}latrobe.edu.au Received July 2, 2009.

Abstract Introduction: The tumour microenvironment is hypoglycaemic, hypoxic and acidotic.

Fax: 585-3945. E-mail: gyost{at}pharm.utah.edu . Received April 18, 2009; accepted August 18, 2009 Abstract Previous work has shown that bioactivation of the cigarette smoke pneumotoxicant 3-methylindole by pulmonary cytochrome P450 enzymes is directly associated with formation of DNA adducts.

A study in the latest issue of the New England Journal of Medicine compares cisplatin with cisplatin plus doxorubicin for standard-risk hepatoblastoma.

Adding doxorubicin to cisplatin for standard-risk hepatoblastoma does not improve resection rates or survival in children with the disease, according to findings from the third study of the International Childhood Liver Tumor Strategy Group .

Giorgio Perilongo, M.D., Rudolf Maibach, Ph.D., Elisabeth Shafford, M.D., Laurence Brugieres, M.D., Penelope Brock, M.D., Bruce Morland, M.D., Beatriz de Camargo, M.D., Jozsef Zsiros, M.D., Derek Roebuck, M.D., Arthur Zimmermann, M.D., Daniel Aronson, M.D., Margaret Childs, Eva Widing, M.D., Veronique Laithier, M.D., Jack Plaschkes, M.D., Jon ...

Ten patients with pathological complete response had significantly higher p53 expression, CD3 lymphocyte and CD83 cell counts, and lower progesterone receptor expression.

Main Category: Ovarian Cancer Also Included In: Cancer / Oncology ; Women's Health / Gynecology Article Date: 18 Oct 2009 - 0:00 PDT Treating women with relapsed platinum-sensitive ovarian cancer with combined carboplatin and pegylated liposomal doxorubicin prolongs progression free survival and is associated with a lower risk of severe, long ...

Main Category: Cancer / Oncology Also Included In: Clinical Trials / Drug Trials Article Date: 16 Oct 2009 ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc. announced today positive top line interim data from the multicenter randomized Phase II trial of palifosfamide treating patients with unresectable or metastatic soft tissue sarcoma.

Abstract Several multigene markers that predict relapse more accurately than classical clinicopathologic features have been developed.

Universidad de Coimbra, s/n. 37007 Salamanca, Spain. E-mail: p_maiso@hotmail.com Received 17 March 2009; Revised 20 July 2009; Accepted 29 July 2009; Published online 8 October 2009.

Anti-cancer drugs access solid tumors via blood vessels, and must penetrate tumor tissue to reach all cancer cells.